Agomab Therapeutics NV Adrs AGMB

$7.95 -0.01 (-0.13%)

Valuation

Market cap
288,446,000
Revenue TTM
$0
Net income TTM
$-70,770,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
575,300
Avg volume
156,212
Day's range
$7.45 – $8.29
Shares out
36,237,000
Stochastic %K
25%
Beta
—
Analysts
Strong Sell
Price target
$37.67

Price

Company profile

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-44...

Show more

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Industry
Biotechnology
Sector
Healthcare
Phone
32 3 318 91 70
Website
https://www.agomab.com
Address
Posthoflei 1/6, Antwerp, Belgium

Latest news

Stocktwits

Achouffe Oct 16, 12:08 PM
Took a first position in $AGMB at $8,2. In sympathy with the CEO 😀 and I hope we don't lose any finger(s)
0 replies
filecrux Oct 13, 9:46 PM
$AGMB Belgian fibro-inflammation biotech Agomab dosed the first patient in its ~320-patient Phase 2b of ontunisertib in fibrostenosing Crohn's, triggering a €7M payment to former Origo Biopharma holders. The €7M is about 2.8% of the €252.0 million in cash, cash equivalents and short-term cash investments Agomab held at June 30, 2026, which the company expects to fund operations into the first half of 2029. Payable so far: €10M of up to €20M; the rest needs further development and regulatory steps. Primary endpoint at Week 24; no readout date given.
0 replies
CEOBuysDisclosures Oct 7, 2:10 PM
$AGMB CEO purchased 11,000 shares at $8.58 for a total of $94,380. Knotnerus Tim Jasper now owns 56,217 shares. https://ceo-buys.com
0 replies
Cache_Money Oct 2, 8:19 PM
$AGMB “At week 48 of the OLE, 97% of evaluate patients were in clinical remission as assessed by the CDAI score… only one FSCD-related event, an EBD procedure, was reported during the study, corresponding to an annualized event rate of 3%. No patients progressed to surgery during up to 60 weeks of ontunisertib 200 mg BID treatment. For reference, while not based on head-to-head studies, recent publications on a comparable FSCD patient population receiving advanced therapies reported annualized event rates ranging from 23-35%” These are some truly amazing results. Congrats to Agomab and Dr. Rieder on making a difference in the lives of patients living with fibrostenosing CD. It’s just a handful so far, but hopefully many more to come.
0 replies
Juhanialainen Oct 2, 7:41 PM
$AGMB I got an alert from bioradar.io about this company. Looks interesting, especially the ownership structure and cash runway. Thinking about buying in longterm.
1 replies
biospeculator Oct 2, 12:21 PM
$AGMB The stock had a small uptick on good results then got liquidated. I was stopped out with a trailing stop. IMO despite these very good results the market is looking forward to an expensive 2b trial that will take some time. Unfortunately, now the ipo investors and most others are in the red. Based on cash burn and time needed we will run into tax loss selling season and probably not see a bottom until Nov/Dec. I look forward to rebuying at that point. GLTA
0 replies
Cache_Money Oct 1, 7:43 PM
$AGMB Wow the OLE data looks great, both for safety and efficacy. That’s a big buy signal for me
0 replies
topstockalerts Oct 1, 3:04 PM
Agomab Therapeutics shares fell during the morning session, reversing a strong premarket gain after the company reported favorable 60-week data from the open-label extension of its Phase 2a STENOVA trial evaluating ontunisertib in patients with fibrostenotic Crohn’s disease. The results showed sustained disease control, a low annualized disease-related event rate of 3%, and no surgeries throughout the treatment period. The data support the company’s planned global Phase 2b NOV-ERA study, expected to enroll about 320 patients. Despite the constructive clinical readout, the intraday reversal reflects a “buy the rumor, sell the news” dynamic often seen in small-cap clinical-stage biotech stocks. Additional selling pressure came after Wall Street Zen downgraded the stock to “Sell” on Sept. 30, one day before the data release. $AGMB
1 replies